Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

e information regarding IXEMPRA, please call 1-888-IXEMPRA (1-888-493-6772) Monday through Friday 8:00 am-5:00 pm ET or visit http://www.IXEMPRA.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee as to when IXEMPRA (ixabepilone) will be commercially available. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ell Report Identifies SPINK1 as a New Biomarker fo...pendia Bioscience, Inc.,the leading provider of ca...unced the central role of their flagship product O... SPINK1 as a key new therapeutic target and,biomar...rowing compendium of nearly 26,000 gene,expression...
...publication on utility of PRDT,s prion reduction t...utzfeldt-Jakob Disease ("vCJD") from ...ing lunchtime Symposium at meeting to discuss prio... product quality., MONTREAL, Canada and CAMBRIDGE... ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic"...
... Iris Recognition Algorithm Detects and Compensate...ctions, VILNIUS, Lithuania, June 10 Neurotechnol...ecognition technology to the,company,s suite of bi...elopment products. VeriEye SDK features an advance...and compensates for partial obstructions,irregular...
Other Biology Technology:Oncomine(TM) Again Key to Prostate Cancer Discovery 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 2New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 3
(Date:12/4/2009)By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How nutrition affects healthy aging 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call 5704 1DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call 5704 2Exposure to Holocaust May Have Raised Cancer Risks 60111 1Exposure to Holocaust May Have Raised Cancer Risks 60111 2Heart Disease Gender Gap Narrows 60108 1Heart Disease Gender Gap Narrows 60108 2Heart Disease Gender Gap Narrows 60108 3
...en peroxide, the same mild acid that many people u...d abrasions, is also produced by the body to keep ...versity School of Medicine have solved how part of...January 3 issue of Nature, a team led by W. Todd L...hot of how two proteins produced by cells interact...
...ions, including the National Academy of Sciences, ...l Science Teachers Association, is calling on the ...e promotion of science education, including evolut...ary 2008 issue of The FASEB Journal, the introduct...igent design, into science education will undermin...
...ay be more than a breath freshener it could spot ...Hopkins Kimmel Cancer Center. Their new study of ...mon to the disease holds promise for screening tho...ol drinkers., Lead investigator Joseph Califano, M...d and neck cancer patients and 527 individuals wit...
Other Biology News:Research explores role of hydrogen peroxide in cell health 2Evolution education is a 'must' says coalition of scientific and teaching organizations 2'Swish-and-spit' test accurate for cancer 2
...cessory lessens the expensive task of validating m... mass spectrometers. It converts the unprocessed d...quadrupole mass spectrometers into analog format a...ory information management (LIMS) systems for proc...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...were designed for full-length gene cloning and req...ed cDNA clone. The first PCR analysis is performed...ains plasmid DNA from 5,000 clones. Having identif... the reaction products, the second PCR analysis is...
...tide Kit, designed for use with Ciphergens Protein... peptides more straightforward and faster than eve...cations - Monitor beta-amyloid expression after dr...ls with disease progression - Evaluate mechanisms ...
Biology Products: